16 August 2024
Intelligent Ultrasound Group
plc
("Intelligent Ultrasound" or the "Group" or the
"Company")
Exercise of share options and
change to total voting rights
Intelligent Ultrasound Group plc
(AIM: IUG), the 'classroom to clinic' ultrasound company,
specialising in artificial intelligence (AI) software and
simulation, announces that it has issued, conditional on admission,
170,000 new ordinary shares of 1 pence each in the capital of the
Company ("Ordinary Shares"), pursuant to the exercise of share
options.
The new Ordinary Shares will rank
pari passu with the existing Ordinary Shares in issue and
application has been made for the new Ordinary Shares to be
admitted to trading on the AIM Market of the London Stock Exchange
("Admission"). Admission is expected to occur, and dealings in the
new Ordinary Shares commence, at 8:00 a.m. on 19 August
2024.
Total Voting Rights
Following Admission, the Company
will have 327,039,921 Ordinary Shares in issue. This figure of
327,039,921 may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change of their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
ENDS
For further information, please
contact:
|
Intelligent Ultrasound Group plc
|
www.intelligentultrasound.com
|
|
Stuart Gall, CEO
|
Tel: +44 (0)29 2075 6534
|
|
Helen Jones, CFO
|
|
|
|
|
|
Cavendish Capital Markets Limited
(Nominated advisor and broker)
|
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Nigel Birks (ECM)
Dale Bellis (Sales)
|
Tel: +44 (0)20 7397 8900
|
|
|
|
|
TB Cardew - PR Advisors
Ed Orlebar
|
Intelligentultrasound@tbcardew.com
Tel: +44 (0)7738 724630
|
|
Allison Connolly
|
Tel: +44 (0)7587 453955
|
|
Emma Pascoe-Watson
|
Tel: +44 (0)7774 620415
|
|
Jessica Pilling
|
Tel: +44 (0)7918 584573
|
|
|
|
|
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM:
IUG) is one of the world's leading 'classroom to clinic' ultrasound
companies, specialising in real-time hi-fidelity virtual reality
simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software
tools for the diagnostic medical ultrasound market ('clinic').
Based in Cardiff in
the UK and Atlanta in the US, the Group has two
revenue streams:
Simulation
Real-time hi-fidelity ultrasound
education and training through simulation. Our main products
are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training
simulator, the BodyWorks Eve Point of Care and
Emergency Medicine training simulator with Covid-19 module and the
new BabyWorks Neonate and Paediatric training simulator. To
date over 1,700 simulators have been sold
to over 800 medical institutions around the
world.
Clinical AI software
Deep learning-based algorithms to
make ultrasound machines smarter and more accessible using our
proprietary ScanNav ultrasound image analysis technology.
Current products on the market utilising this technology
are GE HealthCare's SonoLyst software that is
incorporated in their Voluson Expert and SWIFT ultrasound machines;
ScanNav Anatomy PNB that simplifies ultrasound-guided needling by
providing the user with real-time AI-based
anatomy highlighting for a range of medical procedures; and
NeedleTrainer that teaches real-time ultrasound-guided needling and
incorporates ScanNav Anatomy PNB.
www.intelligentultrasound.com
NOTE: ScanNav Anatomy PNB is CE
approved and cleared for sale in the US by the FDA but is not
available for sale in any other territory requiring government
approval for this type of product.